Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) saw a handy gain
early on Wednesday after the company announced that it received a
recommendation from the Centers for Disease Control and Prevention’s
(CDC) Advisory Committee on Immunization Practices (ACIP). Essentially
the ACIP voted unanimously in favor of including Heplisav-B on its list
of recommended products for use to vaccinate adults against hepatitis B.
Heplisav-B was approved by the U.S. Food and Drug Administration (FDA)
in November 2017 for the prevention of infection caused by all known
subtypes of hepatitis B virus in adults age 18 years and older.
Ultimately, the receipt of the ACIP recommendation is a key step in
providing.
Source: Yahoo News
Thursday, 22 February 2018
Subscribe to:
Post Comments (Atom)
Hello, my name is Jack Sparrow. I'm a 50 year old self-employed Pirate from the Caribbean.
No comments:
Post a Comment